Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
- Stem cells
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28678
The University is the owner of certain Patent Rights (as later defined in this Agreement) relating to a technology developed by John Samuel and Glen Kwon, identified as UA IP# 94108 and described in the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed September 24, 1997), which is a continuation-in-part of the US Patent application No. 08/480,499 (filed June 7, 1995).
Patent Rights means all of the following UA intellectual property
(a) the US Patent application No. 08/480,499 A Method for Eliciting a Thl Specific Immune Response (filed June 7, 1995);
(b) the US Patent application No. 08/737,896 A Method for Eliciting a Thl Specific Immune Response (filed September 24, 1997), a continuation-in-part of 1.6 (a) and later issued as US Patent No. 6,168,804 (issued January 2, 2001);
(c) the US Patent application No. 09/668,825 A Method for Eliciting a Thl Specific Immune Response, a divisional application of 1.6 (b) (filed September 22, 2000);
(d) any US divisional patent applications covering the invention disclosed in the patent application 1.6 (b) above and the resulting patents;
(e) any US continuation-in-part application, and the resulting patents, which are directed to the invention disclosed in the patent applications described in sections 1.6 (b), (c) and (d) above;
(f) any Canadian and foreign patent applications, and the resulting patents, which are based on the invention disclosed in the patent applications described in sections 1.6(e) above; and
(g) any reissues, extensions and divisions of Canadian and foreign patents.
IPSCIO Record ID: 280951
BLP25 is a cancer vaccine being developed by Licensee containing a synthetic 25 amino acid sequence of the MUC-1 cancer mucin encapsulated in a liposomal delivery system and designed to induce an immune response to cancer cells.
IPSCIO Record ID: 308739
Application #11/231,618 – Peptide Analogs capable of enhancing stimulation of a glioma-specific CTL response.
Patent Rights shall mean University intellectual property described below and assigned to University
(a) The United States and foreign patents and/or patent applications listed;
(b) United States and foreign patents issued from the applications listed and from divisionals, substitutions, continuations and continuation-in-parts of these applications;
(c) United States and foreign patents issued from any of the foregoing, including all reissues, registrations, renewals, reexaminations and extensions thereof; and
(d) Claims of U.S. and foreign continuation and divisional applications, and of the resulting patents, which are directed to subject matter specifically described in the U.S. and foreign applications listed.
Licensee is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary therapeutics that target both cancer stem cells, or CSCs, and tumor bulk.
IPSCIO Record ID: 367328
The license granted under this Agreement is granted only to the Licensee and not to any Affiliated Companies. The Licensee will not cross-license the Technology or any Improvements without the prior written consent of University, which consent will not be unreasonably withheld.
The Licensee will not grant sublicenses of the Technology, University Improvements or any Joint Improvements to Affiliated Companies or other third parties without the prior written consent of University which consent will not be unreasonably withheld.
Technology means the Patents and all knowledge, know-how and/or technique or techniques invented, developed and/or acquired, before the Effective Date by University or the Licensee relating to, and including, the technology and materials described, as amended from time to time, including, without limitation all related research, data, specifications, instructions, manuals, papers or other related materials of any nature at all, whether written or otherwise, and Universityâ€™s Confidential Information.
U.S. Provisional filed
April 18, 2003, Serial No.
60/463,952 Hsp27 Antisense to Treat Prostate and other Solid Tumours.
Patents mean collectively the rights in and to any and all inventions which are disclosed in the U.S., Canadian and foreign patents and patent applications identified and all
(i) counterparts, continuations, divisionals, continuations-in-part, continuing prosecution applications, and requests for continued examinations, extensions, term restorations, renewals, reissues, re-examinations, or substitutions thereof;
(ii) corresponding international patent applications;
(iii) corresponding foreign patent applications, including supplementary protection certificates and other administrative protections; and
(iv) international and foreign counterpart patents resulting therefrom, all of which will be deemed added, from time to time.
U.S. Provisional filed October 2, 2002, Serial
No. 60/415,859 Hsp27 Antisense to Treat Prostate and other Solid Tumours.
Product(s) means goods or services manufactured or provided in connection with the use of all or some of the Technology and/or any Improvements.